Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
This is an interventional, parallel arm assignment treatment study in individuals with
Major Depressive Disorder (MDD). Each individual will be treated with a single dose of
pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken
before do...
Age: 21 - 80 years
Gender: All
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
The proposed study is a single-site, randomized, controlled clinical trial (RCT)
comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of
ketamine administered in a medical model without psychotherapy (KET). Eligible study
participants ...
Age: 18 - 90 years
Gender: All
Behavioral Therapy for Crohn's Disease
People living with Crohn's disease (CD) experience psychological and emotional symptoms,
in addition to known chronic and disabling physical symptoms, which prevent them from
living their life to the fullest (flourishing). Depression and anxiety are experienced by
30...
Age: 18 - 65 years
Gender: All
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the long-term safety and tolerability of
BHV-7000, in participants with Major Depressive Disorder (MDD).
Age: 18 - 75 years
Gender: All
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral
stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain
Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive
Disorder (M...
Age: 22 - 70 years
Gender: All
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in
participants with Major Depressive Disorder (MDD)
Age: 18 - 75 years
Gender: All
Neural Circuit Effects of Ketamine in Depression
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Age: 18 - 65 years
Gender: All
DBS for TRD with the Medtronic Percept PC
Of the estimated 30 million Americans who suffer from Major Depressive Disorder,
approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a
region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for
treatment r...
Age: 25 - 70 years
Gender: All
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
In this study, researchers will learn more about a study drug called BIIB122 in participants
with early-stage Parkinson's disease (PD). The study will focus on participants with a
specific genetic variant in their LRRK2 gene.
The main question researchers are tr...
Age: 30 - 80 years
Gender: All
Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Novel invasive neurostimulation stimulation strategies through neurosurgical
interventions are emerging as a promising therapeutical strategy for major depressive
disorder. These have been applied mostly to the anterior cingulate cortex, but other
limbic brain region...
Age: 18 - 80 years
Gender: All
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used
as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat
drug resistant depression using subanesthetic doses. In the hospital setting, intravenous
a...
Age: 18 years - 66+
Gender: All
Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery
Patients presenting for normal spontaneous vaginal delivery who have a neuraxial anesthestic
will be randomized to receive preservative free morphine or saline placebo after delivery.
Age: 18 years - 66+
Gender: Female
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is
superior to a no stimulation control in producing a reduction in baseline depressive
symptom severity, based on multiple depression scale assessment tools at 12 months from
randomizatio...
Age: 18 years - 66+
Gender: All
Telemedicine in Age-Related Macular Degeneration (AMD)
AMD affects 15 million Americans, with 200,000 new advanced cases diagnosed each year. AMD is the leading cause of blindness in this country, from either the “dry” or “wet” advanced forms. At present, there is no treatment for dry AMD. Besides bl...
Age: 50 - 90 years
Gender: All
ToRsemide compArisoN with furoSemide FOR Management of Heart Failure (TRANSFORM-HF)
An approximately 6000-patient, randomized, unblinded, two-arm, multicenter clinical trial comparing torsemide with furosemide among patients hospitalized for heart failure. 1:1 randomization to either oral torsemide OR oral furosemide (dosing at discretion of local pr...
Age: 18 - 85 years
Gender: All